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Abstract
Background: frailty is associated with an increased risk of fragility fractures. Less is known, however, about the association
between frailty and bone health.
Methods: men aged 40–79 years were recruited from population registers in eight European centres for participation in the
European Male Aging Study. Subjects completed a comprehensive assessment which included quantitative ultrasound
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(QUS) scan of the heel (Hologic-SAHARA) and in two centres, dual-energy bone densitometry (dual-energy x-ray absorpti-
ometry, DXA). Frailty was defined based on an adaptation of Fried’s phenotype criteria and a frailty index (FI) was con-
structed. The association between frailty and the QUS and DXA parameters was determined using linear regression, with
adjustments for age, body mass index and centre.
Results: in total, 3,231 subjects contributed data to the analysis. Using the Fried categorisation of frailty, pre-frail and frail
men had significantly lower speed of sound (SOS), broadband ultrasound attenuation (BUA) and quantitative ultrasound
index (QUI) compared to robust men (P < 0.05). Similar results were seen using the FI after categorisation into ‘high’,
‘medium’ and ‘low’ levels of frailty. Using the Fried categorisation, frail men had lower femoral neck bone mineral density
(BMD) compared to robust men (P < 0.05), but not lower lumbar spine BMD. Using the FI categorisation, a ‘high’ level of
frailty (FI > 0.35) was associated with lower lumbar spine BMD (P < 0.05) when compared to those with low (FI < 0.2),
but not lower femoral neck BMD. When analysed as a continuous variable, higher FI was linked with lower SOS, BUA and
QUI (P < 0.05).
Conclusions: optimisation of bone health as well as prevention of falls should be considered as strategies to reduce frac-
tures in frail older people.
Keywords: Frailty, male health, heel ultrasound, bone mineral density, older people
Background
The aging process is characterised by a complex alteration
of anatomical, physiological and psychological factors. In a
significant number of individuals, these changes can result
in frailty, a syndrome that has been defined as ‘an excess
vulnerability to stressors, with reduced ability to maintain
homoeostasis after a destabilising event’ [1]. Frailty is linked
with adverse health outcomes including an increased risk of
falls and institutionalisation [2]. Frailty has also been linked
in prospective studies with an increased risk of future frac-
tures, though whether this is related to the increased sus-
ceptibility to falls or whether there is in addition an
associated reduction in bone strength remains uncertain [3].
Previous studies have investigated the relationship between
frailty and bone mineral density (BMD) [1, 4–11], however,
the results have been somewhat discrepant. Some, though
not all, suggest an association between frailty and markers
of bone strength, including calcaneal BMD [4] and femoral
neck or lumbar spine BMD [5, 6, 8]. However, there are
few data in men. Such data are important; knowledge of the
factors which predispose to fracture, including bone stren-
gth, may help improve targeted preventative measures in
this high risk group. If frailty is linked with reduced bone
strength, then fracture prevention measures should include
not just falls prevention but also measures to optimise bone
strength. The aim of this study was to investigate the rela-
tionship between frailty and bone health defined using both
BMD and quantitative ultrasound (QUS) measurements, in
a population of community dwelling European men.
Methods
Participants
Subjects were recruited for participation in the European Male
Aging Study (EMAS) from eight European centres (Florence,
Italy; Leuven, Belgium; Malmö, Sweden; Manchester, UK;
Santiago de Compostela, Spain; Łódź, Poland; Szeged,
Hungary; Tartu, Estonia). Participants completed a postal ques-
tionnaire and attended a research centre for further assessment.
Ethical approval for the study was obtained in accordance with
local institutional requirements in each centre. Each participant
provided written consent.
Assessments
The postal questionnaire included items concerning health
and lifestyle [12]. Participants were asked also whether they
were currently receiving treatment for a range of medical
conditions. The interviewer assisted questionnaire included
the short form (SF36), the Physical Activity Scale for the
Elderly [13], Reuben’s Physical Performance test [14],
Beck’s Depression Inventory [15] and the Tinetti balance
and postural stability index [16]. A range of anthropometric
measurements were performed including mid-upper arm
circumference (cm) and triceps skinfold thickness (mm).
Body mass index (BMI) was calculated as weight (kg)
divided by the square of height (m).
QUS of the heel
QUS of the left heel was performed in all subjects with the
Sahara Clinical Sonometer (Hologic, Inc, Bedford, MA,
USA) using a standardised protocol in all centres. Outputs
included broadband ultrasound attenuation (BUA, dB/
MHz), speed of sound (SOS, m/s) and quantitative ultra-
sound index (QUI) which is a parameter derived from SOS
and BUA (0.41*SOS+0.41*BUA-571). Short term precision
was measured by performing duplicate measurements in 20
randomly selected subjects from one centre (Leuven,
Belgium). The in vivo coefficients of variation (CVs) were
2.8% and 0.3% for BUA and SOS, respectively. Repeat
measurements (n = 10) were performed on a roving phan-
tom at each of the eight centres. Standardised CVs (SCVs)
for within machine variability ranged by centre: for SOS,
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from 1.0% to 5.6%, and BUA from 0.7% to 2.7%. SCVs
for between machine variability were 4.8% for BUA and
9.7% for SOS [17].
Dual-energy x-ray absorptiometry
Areal bone mineral density (BMDa) scans were carried out
in the Manchester and Leuven subsets of EMAS
(N = 735). Both sites used dual-energy x-ray absorpti-
ometry (DXA) QDR 4500A devices from the same manu-
facturer (Hologic, Inc, Waltham, MA, USA). BMDa was
measured at the lumbar spine (L1–L4) and proximal femur
(total region). The precision errors in Leuven were 0.57%
and 1.28% at the lumbar spine and total femur region,
respectively. In Manchester, these precision errors were
0.97% and 2.04% at the lumbar spine (L1–L4) and prox-
imal femur (total region), respectively. Both devices were
cross-calibrated with the European Spine Phantom [18].
Frailty
Frailty status was determined using a phenotypic definition
adapted from Fried and colleagues based on five criteria: sar-
copenia, exhaustion, slowness, weakness and low activity.
Details of the EMAS frailty phenotype (FP) criteria are
reported elsewhere [19]. Briefly, ‘sarcopenia’ was based on
mid-upper arm muscle circumference (mid-upper arm cir-
cumference – 3.14 × triceps skinfold thickness), the threshold
being the lowest 10% from men over 65 years. ‘Exhaustion’
was defined using BDI-II energy and fatigue items, responses
being ‘I don’t have enough energy to do very much/do any-
thing’ or ‘I am too tired or fatigued to do a lot of/most of the
things I used to’, respectively. ‘Slowness’ from the PPT 50
foot walk test, the threshold being the slowest 20% stratified
by height for men 65 years and older. ‘Weakness’ from the
Tinetti 5 chair stand test, the threshold being the slowest 10%
for those 65 years and over, or who were unable to complete
the test, and ‘low activity’ from the PASE score, the threshold
being the lowest 20% for 65+ years. The Fried frailty category
variable was constructed as follows: 0 criteria = robust (not
frail), 1 or 2 criteria as pre-frail and those with 3 or more cri-
teria as frail. Men with missing data for one or more compo-
nents of the Fried criteria were not included in the analysis.
We also calculated a frailty index (FI). An FI represents the
number of defined health deficits present in an individual
divided by the number of health deficits considered [20, 21].
In EMAS, 39 potential deficits were evaluated and included in
the FI. These represent symptoms, signs or functional impair-
ments that accumulate with age and are individually related to
adverse outcomes. Details of the EMAS FI are reported else-
where [22]. We analysed the FI both as a continuous variable
and as a categorical variable using the threshold levels sug-
gested by Kulminski and colleagues: low (robust), FI ≤ 0.2;
medium (pre-frail), 0.2 < FI ≤ 0.35; and high (frail), FI > 0.35
[23]. Men with missing data for eight components or more
(20%) of the FI were not included in the analysis.
Statistical analysis
Descriptive statistics were used to summarise subject charac-
teristics. Linear regression analysis was used to determine the
association between frailty category (using the phenotype and
FI definitions), and ultrasound and DXA bone parameters,
adjusted for age, centre and BMI with the results expressed
as β-coefficients and 95% confidence intervals (CIs). In these
analyses the β-coefficients represent the absolute difference
in bone parameter among a particular frailty group compared
to the referent value (either the low or robust category).
From the adjusted linear regression models, post estimation
of the marginal mean values of bone parameters for each
frailty category was performed. We looked also at the rela-
tionship between the component features which make up the
FP criteria and bone parameters. We looked also at the asso-
ciation between the FI expressed as a continuous variable
and the bone parameters; in this analysis the β-coefficients
represent the change in FI for each unit change in bone par-
ameter. All statistical analyses were performed using STATA
version 11.2 (http://www.stata.com).
Results
Subject characteristics
A total of 3,369 men were recruited to EMAS. Of these
participants, 29 men were excluded because they were tak-
ing bone active therapies (calcium, vitamin D, bisphospho-
nates, glucocorticoids). A further 109 participants who did
not have QUS of the heel measured at baseline were also
excluded, leaving 3,231 men for analysis. Mean (SD) age of
these subjects was 59.9 (11.0) years and mean (SD) BMI
was 27.6 (4.0) kg/m2. In total, 735 men from the
Manchester and Leuven centres had BMD measurements
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Subject characteristics
Variable Statistic
Heel quantitative ultrasound N = 3231 Mean (SD)
BUA (dB/MHz) 80.3 (18.9)
SOS (m/s) 1550.9 (34.1)
QUI 97.8 (21.2)
Areal bone mineral density N = 735 Mean (SD)
Lumbar spine (g/cm2) 1.055 (0.175)
Femoral neck (g/cm2) 0.807 (0.127)
Frailty index N = 2450 n (%)
Low 2016 (82.3)
Medium 342 (14.0)
High 92 (3.8)
Fried frailty phenotype N = 2965 n (%)
Robust 2110 (71.2)
Pre-frail 783 (26.4)
Frail 72 (2.4)
Components of Fried frailty phenotype N = 2965 n (%)
Low physical activity 305 (10.3)
Exhaustion 239 (8.1)
Slowness 291 (9.8)
Weakness 198 (6.7)
Sarcopenia 168 (5.7)
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performed. Subject characteristics are shown in Table 1.
Based on the Fried definition of frailty, 783 (26.4%) of the
2,965 men in whom it was possible to characterise frailty
were defined as pre-frail and 72 (2.4%) as frail. The propor-
tion of men who were frail increased with age from 0.1% at
age 40–49 years to 6.9% at age 70–79 years. The propor-
tion of men satisfying each of the component criteria varied
from 5.7% (sarcopenia) to 10.3% (low physical activity).
The median FI was 0.09 (IQR 0.04, 0.15). Of the 735 who
also underwent BMD measurement, 151 (20.5%) were pre-
frail and 11 (1.5%) frail using the Fried FP.
FP and bone health
After adjustment, and compared to those who were robust,
frailty defined using the phenotype approach, was associated
with a reduced SOS (β coefficient −17.4; 95% CI −25.4,
−9.4), BUA (β coefficient −10.2; 95% CI −14.6,-5.7) and
QUI (β coefficient −11.4; 95% CI −16.4, −6.5), see Table 2
and also Figure 1. Pre-frailty was linked also significantly
with reduced heel ultrasound parameters though the β coeffi-
cients were smaller. There was no association between frailty
and lumbar spine BMD, though frailty was associated with
reduced femoral neck BMD (β coefficient −0.084; 95% CI
−0.15, −0.014). Each individual component of the FP was
linked with a lower SOS, and this was statistically significant
in the adjusted model for low physical activity, exhaustion,
slow walking speed and weakness, see Supplementary
Table S1, available at Age and Ageing online. The results were
broadly similar for BUA, apart from low physical activity
(QUI and BUA) and weakness (BUA) which were not statis-
tically significant. For femoral neck BMD, low physical activ-
ity, exhaustion, weakness and sarcopenia were linked with
lower BMD though this was statistically significant for exha-
ustion only, see Supplementary Table S1, available at Age and
Ageing online.
FI and bone health
An increase in FI, assessed as a continuous measure, was
significantly associated with lower BUA, SOS and QUI in
the adjusted model, (β coefficient −25.5; 95% CI −33.7,
−17.3, β coefficient −44.8; 95% CI −59.5, −30.0, and β
coefficient −28.7; 95% CI −37.9, −19.6, respectively), see
Figure 1 and Table 2. Compared to those with low FI,
those who were categorised as high FI (FI > 0.35) had sig-
nificantly lower SOS (β coefficient = −11.6; 95% CI −18.9,
−4.3), BUA (β coefficient −7.0; 95% CI −11.1, −3.0), QUI
(β coefficient −7.8; 95% CI −12.3, −3.2) and lumbar spine
BMD (β coefficient −0.13; 95% CI −0.24, −0.024).
Discussion
In this population survey we found a significant association
between frailty and bone health parameters including low
BUA, SOS, QUI and also femoral neck BMD using the
Fried categorisation and lumbar spine BMD using the FI
categorisation, though the magnitude of these effects was
relatively small. There was some evidence of a dose-
response effect with those classified as pre-frail having
BUA, SOS and QUI levels intermediate between those who
were robust and those who were frail. All the component
phenotype criteria were associated with reduced BUA and/
or SOS/QUI though the effect appeared to be more
marked for the slow walking speed and exhaustion criteria.
Epidemiological studies in men and women have shown
that frailty is linked with an increased risk of falls and future
fractures [19, 24–27]. There are, however, surprisingly few
studies which have looked at the link between bone health
and frailty, particularly in men. To our knowledge there are
no data looking at the association between frailty and QUS
parameters. Most cross-sectional studies have shown, after
adjustment for age, no association between frailty and calca-
neal, lumbar spine or femoral neck BMD [6, 8]. One study
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Frailty and bone health parameters
Variable Heel quantitative ultrasound Areal bone mineral density
Adjusted β coefficient (95% CI)a Adjusted β coefficient (95% CI)a
SOS (m/s) BUA (dB/MHz) QUI Lumbar spine Femoral neck
Fried frailty category n = 2961 n = 2961 n = 2961 n = 673 n = 671
Robust Referent Referent Referent Referent Referent
Pre-frail −5.3 (−8.1, −2.4)*** −2.5 (−4.1, −0.9)** −3.2 (−5.0, −1.4)*** 0.00062 (−0.031, 0.032) −0.0021 (−0.024, 0.020)
Frail −17.4 (−25.4, −9.4)*** −10.2 (−14.6, −5.7)*** −11.4 (−16.4, −6.5)*** 0.0044 (−0.096, 0.10) −0.084 (−0.15, −0.014)*
Frailty index category n = 2442 n = 2442 n = 2442 n = 581 n = 580
Low Referent Referent Referent Referent Referent
Medium −8.7 (−12.6, −4.7)*** −5.4 (−7.6, −3.2)*** −5.7 (−8.2, −3.3)*** 0.032 (−0.014, 0.078) −0.0049 (−0.037, 0.027)
High −11.6 (−18.9, −4.3)** −7.0 (−11.1, −3.0)* −7.8 (−12.3, −3.2)** −0.13 (−0.24, −0.024)* −0.019 (−0.0034, −0.0015)
Frialty indexb −44.8 (−59.5, −30.0)*** −25.5 (−33.7, −17.3)*** −28.7 (−37.9, −19.6)*** −0.027 (−0.21, 0.16) −0.083 (−0.21, 0.044)
Lumbar spine and femoral neck BMD is measured in g/cm2.
*P < 0.05; **P < 0.01; ***P < 0.001.
aAdjusted for age, BMI and centre. Results are presented as adjusted β coefficients with robust/low frailty category as the referent group. These results represent
the expected difference in bone parameters for each group, compared to the robust category.
bFI expressed as a continuous measure.
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of older (>65 years) community-dwelling participants (82%
female) found that frailty, defined using a modified
Vulnerable Elders Survey (VES-13), was associated with
lower BMD of the calcaneus, though the prevalence of
frailty was higher than in other comparative studies at 44%
[4]. A prospective study of community-dwelling men aged
70–97 years found no association between baseline frailty,
defined by the Fried FP, and total hip BMD over a mean
follow-up of 2.2 years after adjusting for age [5]. In con-
trast, a study of 235 community-dwelling women aged >70
years, found that frailty at baseline, defined by the VES-13,
predicted lower total hip and lumbar spine BMD 1 year
later, although no association was seen between baseline
frailty and baseline total hip or lumbar spine BMD [9]. The
inconsistency in the literature could, in part, be explained
by differences in study design, sex, age and ethnicity of par-
ticipants and choice of frailty instrument. Our data are con-
sistent with an association between frailty and bone health
parameters. The mechanism linking frailty and bone health
is likely to be multifactorial and include a reduction in mus-
cle mass and strength, reduced loading due to immobility, a
decline in sex hormones, impaired nutrition including
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Figure 1. Marginal mean values (95% CI) of QUS and DXA parameters by FP and FI category
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protein intake, the presence of chronic disease and also dys-
regulated inflammation [28].
Our study has a number of strengths; it was large, popula-
tion based, and used standard methods in both conduct and
assessment. There are though a number of limitations which
need to be considered in interpreting the analysis. The
response rate for participation 41%, with those who declined
to take part being older, more likely to be current smokers
and reporting experiencing less pain lasting at least one day in
the past month, than those who participated [12]. It seems
unlikely, however that any such selection factors would impact
on the findings reported, which were based on internal com-
parison of those who took part. The Fried phenotype defin-
ition of frailty developed in EMAS was adapted from the
original definition, utilising the data available and instruments
used in EMAS. It has though been shown to be associated
with falls, impaired quality of life [19], and mortality [29].
Among those with BMD measurements performed
(N = 735) the prevalence of frailty was lower than those who
did not have the measurements performed (1.5% versus
2.4%). However it seems unlikely that this would have influ-
enced findings concerning the association between BMD and
frailty which was based on an internal comparison of those in
whom measurements were performed.
Men with missing data for one or more components of
the Fried FP were not included in the analysis; again it
seems unlikely that this would have had an influence on our
findings relating to the association between frailty and bone
parameters. Our study was cross-sectional and therefore it
is not possible to determine the temporal nature of the
observed associations. It seems unlikely though that
reduced bone density per se would lead to an increase in
the risk of frailty. Our cohort included younger men (age
<65 years) which may explain the lower proportion of
frailty than observed in other cohorts. Finally, our study
focused on a European population and so the results
should be extrapolated beyond this group with caution.
Our findings are consistent with the view that in add-
ition to an increased susceptibility to falls among frail men,
reduced bone strength contributes to susceptibility to frac-
ture risk. Data from a recent trial among female nursing
home residents suggest that treatment with long-acting
bisphosphonate (zoledronic acid) is linked with an increase
in bone density in this vulnerable group and provides there-
fore a real opportunity for prevention of fractures in this
group based on targeting bone [30, 31].
In conclusion, a reduction in bone strength may in part
explain the increased susceptibility to fracture among frail
older people. Prevention of fractures in frail older people
should include consideration of optimising bone health as
well as preventing falls.
Key points
• Frailty is associated with reduced bone density and heel
ultrasound parameters.
• Pre-frail men have ultrasound parameters intermediate
between robust and frail men.
• Optimisation of bone health should be considered as a
strategy to reduce fractures in frail older people.
Supplementary data
Supplementary data mentioned in the text are available to
subscribers in Age and Ageing online.
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